Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omeprazole + dextromethorphan + midazolam + fexofenadine
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A diagnostic cocktail of four probe drugs—omeprazole, dextromethorphan, midazolam, and fexofenadine—used to assess the phenotypic activity of specific drug-metabolizing enzymes and transporters. Developed by Assistance Publique - Hôpitaux de Paris for the MARVEL study (MetAbolism vaRiability of VEnLafaxine), it evaluates the activity of Cytochrome P450 enzymes (CYP2C19, CYP2D6, CYP3A4) and the P-glycoprotein (P-gp) transporter in patients with major depressive disorder receiving venlafaxine. This research tool helps investigators understand pharmacokinetic variability and its impact on treatment efficacy and tolerance, aiming to advance personalized medicine approaches in psychiatry by identifying individual metabolic profiles.
- Other names
- cocktail probe drugsphenotypic cocktailMARVEL study cocktail
02
Targets
CYP2C19 (Cytochrome P450 2C19)CYP3A4 (Cytochrome P450 3A4)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on omeprazole + dextromethorphan + midazolam + fexofenadine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omeprazole + dextromethorphan + midazolam + fexofenadine.